Considerations in the rational design and conduct of phase I/II pediatric clinical trials: avoiding the problems and pitfalls.
about
Bayesian design using adult data to augment pediatric trials.Changes in individual drug-independent system parameters during virtual paediatric pharmacokinetic trials: introducing time-varying physiology into a paediatric PBPK modelOntogeny of midazolam glucuronidation in preterm infants.Impact of the CYP2C19*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect.Determination of enalapril and enalaprilat in small human serum quantities for pediatric trials by HPLC-tandem mass spectrometry.Clinical trials in childrenObservational infant exploratory [(14)C]-paracetamol pharmacokinetic microdose/therapeutic dose study with accelerator mass spectrometry bioanalysis.Special populations and pharmacogenetic issues in tuberculosis drug development and clinical researchSafety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-experienced HIV-1 Infected Adolescents: Forty-eight-week Results from IMPAACT P1093Early-phase clinical trials in the community: results from the national cancer institute community cancer centers program early-phase working group baseline assessment.Single-dose pharmacokinetics and safety of azilsartan medoxomil in children and adolescents with hypertension as compared to healthy adults.Pediatric high grade glioma: a review and update on tumor clinical characteristics and biology.Limited impact of EU paediatric regulation on Finnish clinical trials highlights need for Nordic collaboration.Present state and future challenges in pediatric abdominal pain therapeutics research: Looking beyond the forest.Knowledge of developmental pharmacology and modeling approaches should be used to avoid useless trials in childrenStability of sunitinib in oral suspension.Safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including biological products) in neonates.
P2860
Q33492143-0262B80A-D142-46DC-A401-10EBCA180A28Q33574126-54FB4C79-5519-4AB1-8F3D-EC6C4CEB7540Q33587843-FBB73505-63BC-4015-AAE4-84200E60D327Q33891049-671B2236-57DD-4E68-829A-6438E7432517Q34033336-1C7605A8-ADF7-4632-9923-BC5A032F02CBQ35135928-639A74C1-6A38-458B-80BE-6E8E0A2F6DF4Q35846147-9313EFDA-AEF8-4949-AE7A-78822F2C26B1Q36000004-2A1EF8E9-58BA-461A-9A74-DCB0AF1049C8Q36157266-FE7E93F5-E296-49F7-9BC1-C28638E15F64Q36678241-802C24C1-4D4A-4BDE-84C2-7B0310D27E44Q36688528-D729846F-D0E6-4B62-903C-A218869601DEQ38039443-2E24C256-1B9B-435E-B4C8-68CD4B13CB79Q38124376-5D94FF69-B3D2-439C-A499-1D38C70C95B3Q38630447-128202CC-EB66-43C9-982A-AE658CF81FDBQ42569176-B5678D35-2D67-46DB-8325-AE833A5EB887Q46520429-E6496B72-C76F-4666-9037-C6CFB5E19895Q47428031-5268260D-65FE-4AD5-9EAB-0633B9B5E4FB
P2860
Considerations in the rational design and conduct of phase I/II pediatric clinical trials: avoiding the problems and pitfalls.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Considerations in the rational ...... ing the problems and pitfalls.
@en
type
label
Considerations in the rational ...... ing the problems and pitfalls.
@en
prefLabel
Considerations in the rational ...... ing the problems and pitfalls.
@en
P2093
P2860
P356
P1476
Considerations in the rational ...... ing the problems and pitfalls.
@en
P2093
Abdel-Rahman SM
P2860
P304
P356
10.1038/SJ.CLPT.6100134
P407
P577
2007-02-28T00:00:00Z